Trial Search Results
Brain Imaging of rTMS Treatment for Depression
The overarching goal of this research program is to elucidate causal and directional neural network- level abnormalities in depression, and how they are modulated by an individually-tailored, circuit-directed intervention. By using concurrent TMS and fMRI, the investigators can overcome a major limitation of neuroimaging - the inability to demonstrate causality. The investigators' findings will serve as a platform for future studies wherein TMS treatment can be directly guided by the investigators' ability to image and causally manipulate specific neural networks.
Aim 1: To examine causal interactions between two major brain networks in depression.
Aim 2: To examine the impact of antidepressant TMS on causal network abnormalities in depression.
Hypothesis 1: Depressed subjects will show blunted responses, compared to healthy controls, in two targeted and interacting networks, using concurrent transcranial magnetic stimulation (TMS) and functional magnetic resonance imaging (fMRI).
Hypothesis 2: Treatment of patients with high-frequency repetitive TMS (rTMS) will result in normalization of baseline network-level deficits, and be predicted by degree of baseline network abnormalities.
Stanford is currently not accepting patients for this trial.
Collaborator: The Dana Foundation
- Device: rTMS Treatment
- Device: Sham rTMS Treatment
- Men and women, ages 18 to 50
- Depression assessed through phone screen
- Must comprehend English well to ensure adequate comprehension of the fMRI and TMS
instructions, and of clinical scales
- Has failed >1 previous adequate antidepressant medication trials
- No current or history of neurological disorders
- No seizure disorder or risk of seizures
- Any contraindication to being scanned in the 3T scanners at the Lucas Center or CNI
such as having a pacemaker or implanted device that has not been cleared for scanning
at the Lucas Center or CNI
- Any unstable medical condition, any significant CNS neurological condition such as
stroke, seizure, tumor, hemorrhage, multiple sclerosis, etc
- Current rTMS treatment or prior treatment failure with rTMS
- Current electroconvulsive therapy (ECT) or prior treatment failure with ECT
- Currently pregnant or breastfeeding
Ages Eligible for Study
18 Years - 50 Years
Genders Eligible for Study